학술논문

Complement Factor H is a Novel Biomarker for Diagnosis and Prognosis of Patients with Liver Cancer.
Document Type
Article
Source
Indian Journal of Pharmaceutical Sciences. 2022 Special Issue2, Vol. 84, p48-58. 11p.
Subject
*COMPLEMENT factor H
*CANCER prognosis
*DNA repair
*COMPLEMENT receptors
*PROGRESSION-free survival
*COMPLEMENT activation
*BIOMARKERS
*SURVIVAL analysis (Biometry)
Language
ISSN
0250-474X
Abstract
The complement system played critical roles in antimicrobial defense response, immune regulation and immunopathological damage. As an important negative regulator in this system, complement factor H provided selective advantage for tumor cell proliferation to escape immune surveillance, leading to avoid apoptosis. However, the influence of its expression on the pathological process and prognosis of liver cancer were still unclear. In this study, we analyzed the pattern of complement factor H expression in liver cancer in order to clarify its potential application value in the diagnosis and prognosis by bioinformatics analysis of data-set collected from The Cancer Genome Atlas database. By evaluating the clinical diagnostic value of complement factor H, we studied the correlation between complement factor H expression and clinicopathological parameters of liver cancer. Additionally, we found that patients with low complement factor H expression had poor overall survival and relapse-free survival, and confirmed that low complement factor H expression was an independent predictor of poor prognosis through risk regression analysis. Gene-set enrichment analysis identified E2 factor targets, growth 2 phase of mitosis checkpoint, spermatogenesis, mitotic spindle, deoxyribonucleic acid repair and wingless-related integration site/beta-catenin signaling were enriched with low complement factor H expression phenotype. Taking together, these findings suggested that complement factor H may be a useful biomarker for the diagnosis and prognosis of liver cancer. [ABSTRACT FROM AUTHOR]